British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis.
Date
2020-07-01Author
Powell, N
Ibraheim, H
Raine, T
Speight, RA
Papa, S
Brain, O
Green, M
Samaan, MA
Spain, L
Yousaf, N
Hunter, N
Eldridge, L
Pavlidis, P
Irving, P
Hayee, B
Turajlic, S
Larkin, J
Lindsay, JO
Gore, M
Type
Journal Article
Metadata
Show full item recordAbstract
Immune checkpoint inhibitors are a novel class of cancer treatment that have improved outcomes for a subset of cancer patients. They work by antagonising inhibitory immune pathways, thereby augmenting immune-mediated antitumour responses. However, immune activation is not cancer-specific and often results in the activation of immune cells in non-cancer tissues, resulting in off-target immune-mediated injury and organ dysfunction. Diarrhoea and gastrointestinal tract inflammation are common and sometimes serious side-effects of this type of therapy. Prompt recognition of gastrointestinal toxicity and, in many cases, rapid institution of anti-inflammatory or biologic therapy (or both) is required to reverse these complications. Management of organ-specific complications benefits from multidisciplinary input, including engagement with gastroenterologists for optimal management of immune checkpoint inhibitor-induced enterocolitis. In this British Society of Gastroenterology endorsed guidance document, we have developed a consensus framework for the investigation and management of immune checkpoint inhibitor-induced enterocolitis.
Collections
Subject
Adrenal Cortex Hormones
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Consensus
Endoscopy
Endoscopy, Digestive System
Enterocolitis
Gastroenterology
Gastrointestinal Diseases
Guidelines as Topic
Humans
Infliximab
Lactoferrin
Leukocyte L1 Antigen Complex
Neoplasms
Patient Care Management
Societies, Medical
Tumor Necrosis Factor-alpha
United Kingdom
Language
eng
Date accepted
2020-01-21
License start date
2020-07-01
Citation
The Lancet Gastroenterology & Hepatology, 2020, 5 (7), pp. 679 - 697
Publisher
ELSEVIER INC